REVB.NASDAQRevelation Biosciences, INC

10-K: Revelation Biosciences Reports 2024 Results, Initiates Phase 1b Study in CKD Patients

Sentiment:

Annual Results

📋All filings for Revelation Biosciences, INC
🔒Login to Follow

Revelation Biosciences, a clinical-stage life science company, announces its 2024 financial results and the start of a Phase 1b clinical study for Gemini-CKD in chronic kidney disease patients.

Capital raiseThe company plans to seek additional funding through public or private equity or debt financings.
Worse than expectedThe company's net loss increased significantly compared to the previous year.The company's accumulated deficit increased.The company's cash and cash equivalents decreased.The company anticipates that its current cash and cash equivalents balance will not be sufficient to sustain operations within one-year after the date that its audited financial statements for December 31, 2024 were issued, which raises substantial doubt about its ability to continue as a going concern.

Summary

  • Revelation Biosciences is a clinical-stage life science company focused on rebalancing inflammation to optimize health.
  • The company's lead product, Gemini, is being developed for acute kidney injury (AKI), chronic kidney disease (CKD), and post-surgical infection (PSI).
  • In January 2025, Revelation Biosciences began a Phase 1b clinical study in CKD patients to support further development of Gemini-AKI and Gemini-CKD, with data expected in the first half of the year.
  • The company incurred a net loss of $15.0 million for the year ended December 31, 2024, and had an accumulated deficit of $40.5 million.
  • As of December 31, 2024, Revelation Biosciences had cash and cash equivalents of $6.5 million.
  • The company anticipates that its current cash and cash equivalents balance will not be sufficient to sustain operations within one-year after the date that its audited financial statements for December 31, 2024 were issued, which raises substantial doubt about its ability to continue as a going concern.
  • Revelation Biosciences plans to seek additional funding through public or private equity or debt offerings.
  • The company's common stock and warrants are traded on the Nasdaq Capital Market under the symbols REVB and REVBW, respectively.
  • As of March 3, 2025, there were 522,223 shares of common stock outstanding.
  • The company effected a 1-for-16 reverse stock split on January 28, 2025.
  • The company is subject to risks related to product development, regulatory approval, competition, and reliance on third parties.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is progressing with clinical trials, the significant net loss and going concern uncertainty weigh heavily on the sentiment.

Positives

  • Revelation Biosciences is advancing its Gemini platform through clinical trials.
  • The company has initiated a Phase 1b study in CKD patients, indicating progress in its clinical development pipeline.
  • The company regained compliance with Nasdaq listing requirements.

Negatives

  • Revelation Biosciences reported a significant net loss of $15.0 million for 2024.
  • The company has an accumulated deficit of $40.5 million.
  • The company anticipates that its current cash and cash equivalents balance will not be sufficient to sustain operations within one-year after the date that its audited financial statements for December 31, 2024 were issued, which raises substantial doubt about its ability to continue as a going concern.
  • The company has a limited operating history and no products approved for commercial sale.

Risks

  • The company's ability to continue as a going concern is uncertain.
  • Raising additional funding may cause dilution to existing stockholders.
  • Clinical studies may be unsuccessful or delayed.
  • The company faces intense competition in the biopharmaceutical industry.
  • The company relies on third parties for manufacturing and clinical studies.
  • The company may be unable to obtain and maintain effective patent rights.

Future Outlook

The company expects to continue to generate operating losses and negative operating cash flows for the foreseeable future and plans to seek additional funding through public or private equity or debt financings.

Industry Context

The biopharmaceutical industry is intensely competitive and subject to rapid innovation and significant technological advancements.

Stakeholder Impact

  • Shareholders may experience dilution if the company raises additional capital through equity offerings.
  • Employees face uncertainty due to the company's financial situation.
  • The company's ability to develop and commercialize products may be affected by its financial constraints.

Next Steps

  • Continue Phase 1b clinical study in CKD patients.
  • Seek additional funding through public or private equity or debt offerings.
  • Continue development of Gemini for AKI, CKD, and PSI.

Key Dates

DateDescription
November 20, 2019Revelation Biosciences, Inc. was incorporated in Delaware.
January 31, 2021Old Revelation issued warrants to purchase shares of its common stock to a placement agent in connection with a prior private placement of its securities.
July 27, 2021Effective date of Executive Employment Agreements with James Rolke and Chester S. Zygmont, III.
January 25, 2022The Company issued warrants to an institutional investor to purchase up to 154 shares of common stock at an exercise price of $ 55,272.00 per share.
July 28, 2022The Company issued 8,333,334 Class B Common Stock Warrants to purchase an aggregate of 497 shares of common stock at an exercise price of $ 10,080.00 per share.
January 30, 2023Stockholders approved a Certificate of Amendment to change the authorized common stock from 100,000,000 to 500,000,000 shares and effect a reverse stock split.
February 1, 2023The Company effected a 1-for-35 reverse stock split.
February 13, 2023The Company closed a public offering of common stock, pre-funded warrants, and common stock warrants.
January 25, 2024The Company effected a 1-for-30 reverse stock split.
February 5, 2024The Company closed a public offering of common stock, pre-funded warrants, and common stock warrants.
June 11, 2024The Company issued 653 shares of common stock to a third party consultant in order to induce the holders of the Class D Common Stock Warrants, as a result the exercise price of the Class D Common Stock Warrants were reduced from $ 72.48 to $ 38.24.
August 22, 2024The Company entered into warrant exercise inducement offer letters with certain holders of Class D Common Stock Warrants to exercise their warrants at a reduced exercise price of $ 20.00 per share, in exchange for the Companys agreement to issue new warrants for $ 2.00.
December 3, 2024The Company entered into warrant exercise inducement offer letters with the holders of the Class E Common Stock Warrants to exercise their warrants at an exercise price of $ 16.00 per share, in exchange for the Companys agreement to issue Class F Common Stock Warrants and Class G Common Stock Warrants.
January 28, 2025The Company effected a 1-for-16 reverse stock split.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.